A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction

Inclusion Criteria: 1）Voluntary participation and signing of informed consent; 2\) Aged ≥18 years and ≤75 years and BMI≤28kg/m2, regardless of gender; 3\) Patients undergoing elective laparoscopic-assisted intestinal resection and the surgical site is part of the intestinal segment from the ileocecal region to the sigmoid colon; 4\) Vital organ functions meet the following requirements:iver function: ALT and AST≤3×ULN, total bilirubin level≤2×ULN; Renal function: serum creatinine (Cr)≤1.5×ULN or creatinine clearance≥50mL/min (when Cr\>1.5×ULN); Blood routine examination: hemoglobin (HGB)≥80g/L; Blood biochemistry: albumin (ALB)≥30g/L; 5\) Those classified as physical condition 1 to 3 by the American Society of Anesthesiologists (ASA). Exclusion Criteria: 1\) Patients with a history of clinically significant drug allergy or known allergy to the study drug ingredients and excipients; 2）Those who have a history of severe heart, lung, liver, kidney, blood, endocrine, immune, skin, neurological or mental diseases in the past two years or currently have diseases of the above systems; 3\) Those with a history of drug abuse in the past 6 months; 4\) Those with a history of constipation in the past 6 months (less than 3 bowel movements per week); 5\) Severe mechanical intestinal obstruction that is not expected to be relieved after surgery, short bowel syndrome, significant gastrointestinal motility disorders (such as gastroparesis, scleroderma, chronic intestinal pseud…